You searched for "Immunotherapy"

198 results found

Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer

Despite prostate cancer being one of the most commonly diagnosed cancers worldwide, there remains a need for high-quality evidence regarding the optimal treatment choice. In this large population-based cohort study, using the PCBaSe Sweden dataset, Sooriakumaran and colleagues identified patients...

Focal therapy for prostate cancer – ready for prime time?

The current therapeutic ratio for radical therapy in many men with localised prostate cancer is not ideal. For a significant side-effect profile, there seems to be a small survival benefit over a 10-15 year period. A strategy that might balance...

Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy

The functional side-effects of both radical prostatectomy and radiotherapy for prostate cancer are well known. The aim of this study was to evaluate if there was a significant worsening in recovery of urinary continence in those undergoing radical prostatectomy followed...

Dilemma of second primary tumour

Long-term survival in localised prostate cancer (CaP) can be achieved with treatment by either radical prostatectomy (RP) or external beam radiotherapy (EBRT). The development of second primary tumour is poorly understood in such cases. This retrospective study included 84,397 cases...

ACP (Association for Continence Professionals) Annual Conference 2025

The main programme will be of interest to, Bladder and Bowel Nurses, Physiotherapists, Occupational Therapists, Urology Nurses, and Specialist Nurses as well as Doctors, Nurses and Allied Healthcare Professionals working within, or interested in Continence Care.

Save the orchid

In many urological cancers there is currently more and more inclination for organ-preserving surgery but in patients with germ cell tumours (GCT), radical orchidectomy remains the gold standard. Can we somehow save the testes? This study aims to summarise published...

Penile cancer: a practical approach

Penile cancer is rare and accounts for less than 1% of all new cancer cases in males in the UK, with around 640 new cases diagnosed every year [1]. In England and Wales, the annual incidence is between 1.2 and...

Adjuvant radiotherapy versus wait-and-see after radical prostatectomy

Optimum treatment modalities in prostate cancer continue to evolve, with debates at each stage of the evolution process, from focal therapy to radical treatment. In this randomised study, Wiegel et al. investigated the role of adjuvant radiotherapy following open radical...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

Cryotherapy in prostate cancer

This review of the literature aims to summarise what is known in regards to outcomes in patients undergoing cryotherapy in a number of settings: whole gland, salvage and targeted focal therapy. It highlights that more prostate cancers are being diagnosed...

Stereotactic body radiotherapy for oligometastatic disease secondary to urological cancer

The concept of oligometastatic disease is controversial. The traditional model of cancer, which most of us learnt at medical school, is of a disease which starts confined to an organ, for example the prostate, where it can be cured with...

EAU Patient Information 2019

Credible sources of medical information are difficult to find for patients and healthcare professionals. The European Association of Urologists (EAU) have updated their patient information website since our previous review last year. This digital review focuses on the patient information...